Cardiotoxicity and Cancer Therapy

Кардиотоксичность и противоопухолевая терапия
Genovefa D. Kolovou, Ioannis K. Vasiliadis, Dimitri P. Mikhailidis
2013-08-05

VEGF signaling inhibitionanthracyclinescancer therapycardiotoxicitychemotherapy-induced cardiovascular complications
A fundamental concept of treatment is to do no harm. However, with cancer treatment this is not always possible. \nChemotherapy is associated with cardiovascular (CV) complications.1,2 This risk is even greater in the elderly patients and patients with established CV disease. More specifically, tachyarrhythmias (eg, cisplatin), bradyarrythmias (eg, paclitaxel), or QT prolongation (eg, dasatinib) have been reported. Furthermore, myocardial necrosis, coronary vaso-occlusion or vasospasm, pericardial disease (eg, cytarabine), endocardial fibrosis (eg, busulfan), and heart failure can occur. Hypotension (eg, fludarabine) or hypertension (eg, vinca alkaloids) has also been reported.1,2 Cardiotoxicity, endothelial injury, and Takotsubo syndrome have been reported in patients treated with 5-fluorouracil (5-FU).3⇓–5 Cardiotoxicity to 5-FU was reported 35 years ago.3⇓–5 Cardiotoxicity of chemotherapy has been reported in patients ranging from children through adults (eg, with anthracyclines or cisplatin).6 Adriamycin-induced myocyte damage has been attributed to the production of toxic oxygen free radicals.7 This can cause lipid peroxidation of membranes resulting in vacuolation, irreversible damage, and myocyte replacement by fibrous tissue.7 \nThe use of angiogenesis inhibitors in cancer therapy is expanding as are the associated adverse CV effects (eg, hypertension, thromboembolism, left ventricular dysfunction, and QTc prolongation).2,8 Vascular endothelial growth factor (VEGF) plays a role in maintaining vascular homeostasis via the production of the vasodilator nitric oxide (NO) and decreased vascular resistance through the generation of new blood vessels.2,8 Therefore, it is not surprising that inhibition of VEGF signaling (eg, … \n[Full Text of this Article]
1
Anthracycline-associated myocardial damage has been attributed to toxic oxygen free radicals, causing membrane lipid peroxidation, irreversible myocyte injury, and replacement by fibrous tissue.
2
Cancer therapies can cause diverse cardiovascular complications, including arrhythmias, QT prolongation, myocardial injury, coronary events, pericardial and endocardial disease, blood-pressure abnormalities, and heart failure.
3
Cardiotoxicity risk is particularly increased in elderly patients and those with pre-existing cardiovascular disease.
4
Expanding use of angiogenesis inhibitors is associated with hypertension, thromboembolism, left-ventricular dysfunction, and QTc prolongation, consistent with cardiovascular effects of inhibiting VEGF-mediated vascular homeostasis.
5
Specific chemotherapeutic agents are associated with distinct cardiovascular toxicities, including cisplatin-related tachyarrhythmias, paclitaxel-related bradyarrhythmias, dasatinib-related QT prolongation, and 5-fluorouracil-associated cardiotoxicity, endothelial injury, and Takotsubo syndrome.

Cardiotoxicity associated with cancer therapies, including chemotherapy and angiogenesis inhibitors

Cardiovascular complications and mechanisms of cardiac and vascular injury caused by cancer treatments

Publication Details
Publication Date
2013-08-05
Journal
Publisher
ISSN
Cited by
19
Access Type
Author Information
Authors
Genovefa D. Kolovou
Ioannis K. Vasiliadis
Dimitri P. Mikhailidis
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%